 OPKO Health Inc NASDAQ: OPK has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation CAMP4 to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology. AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein. 